iiinova — where your digital self keeps evolving

Biotech Stock Daily @biotechstockdaily.bsky.social · 16/10/2026

New sensor patch market forecast: $28.9B by 2031 at 29.6% a year. We checked it against Dexcom and iRhythm guidance and other research firms' estimates. #Skin #Health #Biotech Disclaimer: This is NOT a financial advice

100 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 15/10/2026

How big is the biopsy device market? Depends who you ask. Mordor Intelligence says $2.33B in 2026, rising to $2.83B by 2031. Other research firms put it higher and growing faster. #Biopsy #Biotech Disclaimer: This is NOT a financial advice

100 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 14/10/2026

Phase 3 TRIUMpH-NERD data at ACG 2026: tegoprazan met its primary and key secondary heartburn endpoints in non-erosive reflux disease. FDA review ongoing. #GERD #Gastroenterology #Biotech Disclaimer: This is NOT a financial advice

100 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 14/10/2026

Innovent's Sycume met its Phase 3 primary endpoint in inactive thyroid eye disease, with a 60.4% proptosis response vs. 23.5% on placebo at Week 24. #Thyroid #Biotech Disclaimer: This is NOT a financial advice

121 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 13/10/2026

Cullinan begins its potentially registrational Phase 2 study of CLN-049 in relapsed or refractory acute myeloid leukemia. #Leukemia #Biotech Disclaimer: This is NOT a financial advice

100 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 13/10/2026

Hemostemix secures Bahamas approval for a Phase 1 study of its investigational VesCell therapy. #Biotech #Biotechnology Disclaimer: This is NOT a financial advice

111 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 12/10/2026

Ribo has filed an EU application to begin a Phase 1 trial of RBD3133, an INHBE-targeting siRNA for overweight and obesity. #Obesity #Biotech Disclaimer: This is NOT a financial advice

100 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 12/10/2026

Astellas previewed 21 ESMO 2026 abstracts on Padcev, Vyloy, Xtandi and setidegrasib. The release lists titles and time slots but no efficacy or safety figures. #Oncology #Biotech #Medicine Disclaimer: This is NOT a financial advice

121 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 09/10/2026

TempraMed’s VIVI Cap Smart now supports Apple Health and Google Fit connectivity for injectable-medication tracking. #Google #Apple #Health Disclaimer: This is NOT a financial advice

110 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 09/10/2026

Marvel Biosciences signs a CRO letter of intent for the planned first human trial of MB-204 in Australia. #Biotech #Biotechnology #Trial #Australia Disclaimer: This is NOT a financial advice

221 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 08/10/2026

First-in-human RAG-18 data at WMS 2026: higher utrophin in muscle biopsies from three boys with Duchenne, clean early safety, mixed function results. Tiny, uncontrolled, and very early. #Biotechnology #Biotech Disclaimer: This is NOT a financial advice

000 0

Reposted by Biotech Stock Daily

Biotech Stock Daily @biotechstockdaily.bsky.social · 08/10/2026

Phase 3 ACHIEVE-4: Lilly's oral GLP-1 Foundayo showed no added heart risk vs. insulin glargine in type 2 diabetes, with better A1C and weight results. #Biotech #Diabetes #Discovery Disclaimer: This is NOT a financial advice

022 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 08/10/2026

022 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 07/10/2026

Surrozen receives FDA clearance to begin the Phase 1b/2a DUET trial of SZN-8141 in diabetic macular edema. #Biotech #Biotechnology #Health #Trial Disclaimer: This is NOT a financial advice.

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 07/10/2026

Novartis licenses Abogen's mRNA-encoded T-cell engager ABO2203 for $575M upfront. Option terms, royalty rates, and the milestone split were not disclosed. #Biotech #Biotechnology #Health

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 06/10/2026

Ontario's Life Sciences Scale-Up Fund is covering 33% of a C$5.3M upgrade at Piramal Pharma's Aurora drug substance plant. The release skips the timeline and the equipment details. #Biotech #Biotechnology #Pharma Disclaimer: This is NOT a financial advice.

021 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 06/10/2026

Cartesian reports additional Descartes-08 retreatment data from five myasthenia gravis patients ahead of its Phase 3 readout. #Biotech #Biotechnology #Health Disclaimer: This is NOT a financial advice

010 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 05/10/2026

$MONY.P and Vimy Pharmaceuticals sign a definitive RTO agreement after Vimy closes a C$12.06M financing. Its generic semaglutide submission remains under Health Canada review. #Biotech Disclaimer: This is NOT a financial advice

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 05/10/2026

Ascletis' oral IL-17A inhibitor ASC50 posted early Phase 1 data in plaque psoriasis: a 48.9% placebo-adjusted PASI reduction after 28 days. Small study, milder patients, more work ahead. #Biotech #Biotechnology #Phase1 Disclaimer: This is NOT a financial advice

010 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 01/10/2026

First patient enrolled in COMPASSION-37, Akeso's global Phase 3 of cadonilimab in first-line HER2-negative gastric cancer. Comparator: chemotherapy with or without nivolumab. #GastricCancer #Biotech #Oncology Disclaimer: This is NOT a financial advice

010 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 30/09/2026

Zymeworks has completed its acquisition of Theravance Biopharma, expanding its commercial portfolio through YUPELRI profit-share revenue and additional royalty assets. #Biotech #BiotechStocks #Pharma Disclaimer: This is NOT a financial advice

011 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 30/09/2026

FDA authorized Zoetis's Simparica Trio for emergency treatment of screwworm in dogs. The FDA's summary shows the drug worked mainly by expelling larvae, based on one small lab study. #AnimalHealth #VetMed #FDA #Biotech Disclaimer: This is NOT a financial advice

033 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 29/09/2026

Sobi will present four Gamifant (emapalumab) posters in primary HLH at the Histiocyte Society meeting in Rotterdam. The release discloses no results ahead of the Sept. 29 session. #Biotech #Biotechnology Disclaimer: This is NOT a financial advice

010 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 29/09/2026

Oruka reports deeper Week 28 psoriasis responses for ORKA-001 following two induction doses. The results come from a small Phase 2a trial. #Biotech #BiotechStocks #ClinicalTrials #Phase2 Disclaimer: This is NOT a financial advice

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 25/09/2026

GRAIL’s Galleri multi-cancer blood test heads to an FDA advisory panel after the release of agency briefing materials. #Biotechnology #Oncology #Biotech Disclaimer: This is NOT a financial advice.

011 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 25/09/2026

A global Phase 2 trial is testing TML-6, an investigational oral therapy for early Alzheimer's disease that targets the brain's own protein-clearing machinery rather than amyloid plaque directly. #Alzheimers #Biotech #Biotechnolgy Disclaimer: This is NOT a financial advice.

012 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 24/09/2026

Telix Pharmaceuticals has agreed to acquire radioisotope maker ITM Isotope Technologies Munich for $1.65 billion upfront, adding a major lutetium-177 supply chain to its cancer drug portfolio. #Radiopharmaceuticals #Biotech #MergersAndAcquisitions Disclaimer: This is NOT a financial advice

011 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 24/09/2026

Longeveron’s Phase 2b trial of laromestrocel in infants with hypoplastic left heart syndrome missed its primary endpoint. Further analyses and FDA discussions are planned. #Biotech #Biotechnology #Trial Disclaimer: This is NOT a financial advice

031 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 23/09/2026

Ultragenyx has received FDA approval for Fayuvi, the first treatment for pediatric Sanfilippo syndrome type A. The one-time gene therapy addresses the disease’s underlying enzyme deficiency. Disclaimer: This is NOT a financial advice

031 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 23/09/2026

Final Phase 1/2 data for Skyhawk's SKY-0515 in Huntington's disease show sustained benefit at 15 months, measured against a historical patient database rather than a concurrent placebo group. #Biotech #Biotechnology #Trial Disclaimer: This is NOT a financial advice

011 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 23/09/2026

Telo Genomics reports higher residual-myeloma detection with its experimental blood test. The comparison involved only 42 matched samples, and larger validation studies are needed. #Biotechnology #Oncology #Health Disclaimer: This is NOT a financial advice

011 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 22/09/2026

Optimi Health plans a Canadian Phase 3 trial of MDMA-assisted therapy for PTSD in veterans and frontline workers. #PTSD #Veterans #Therapy Disclaimer: This is NOT a financial advice

011 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 22/09/2026

A federal review of 1992-era lab-testing rules is asking how AI should be regulated. ADLM's new comment letter argues AI tools should follow existing CLIA quality standards, not a separate system. #AI #Biotechnology Disclaimer: This is NOT a financial advice

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 21/09/2026

Phase 3 REZILIENT3 data: zipalertinib plus chemotherapy significantly extended progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC. #Biotech #Biotechnology #Oncology Disclaimer: This is NOT a financial advice.

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 21/09/2026

Phase III trial data shows Tam-Peli, a B7-H3-targeted antibody-drug conjugate licensed to Roche, significantly improved survival versus topotecan in relapsed small-cell lung cancer. #Oncology #LungCancer #Biotech Disclaimer: This is NOT a financial advice

054 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 18/09/2026

Medicus Pharma selected the 200 µg SkinJect patch for further development after its Phase 2 basal cell carcinoma study. #Biotech #Pharma #Medicus #Health Disclaimer: This is NOT a financial advice

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 17/09/2026

Gan & Lee Pharmaceuticals has dosed the first participant in a Phase 1 trial of GZC8072, an experimental once-weekly oral peptide GLP-1 receptor agonist. #GLP1 #Biotech #Obesity Disclaimer: This is NOT a Financial advice.

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 17/09/2026

Genflow’s SIRT6 study in aged beagles met its biological-age endpoint. Full results are due October 2. #Pets #Dog #Biotech #Therapy Disclaimer: This is NOT a financial advice

021 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 15/09/2026

Upstream Bio reports a 56% reduction in severe-asthma exacerbations in the Phase 2 VALIANT trial of verekitug. #Asthma #Biotech #Biotechnology #HealthInnovation Disclaimer: This is NOT a financial advice

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 14/09/2026

CorrectSequence Therapeutics has published new Cell Stem Cell data on its base-editing therapies for sickle cell disease and beta-thalassemia across diverse genetic backgrounds. #Genes #DNA #Biotech #Innovation #Genetics Disclaimer: This is NOT a financial advice.

010 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 14/09/2026

Clover Biopharmaceuticals has reported positive Phase 2 data for combination vaccine candidates targeting RSV, hMPV, and PIV3 in older adults. #HIV #Vaccine #Health #Biotech #Biotechnology Disclaimer: This is NOT a financial advice

031 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 08/09/2026

Thryv Therapeutics has licensed a new class of SGK1 inhibitor compounds from Spanish researchers, extending its platform toward Parkinson's and Alzheimer's disease. #Biotech #Biotechnology #Health #Alzheimer #Parkinsons #Research Follow Us for More! Disclaimer: This is NOT a financial advice

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 08/09/2026

TScan is pausing its Phase 3 TSC-101 trial and cutting approximately 75% of its workforce in a major strategic reset. Follow Us for More! Disclaimer: This is NOT a financial advice

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 08/09/2026

HUTCHMED signs a deal worth up to US$1.295B with GSK for experimental cancer therapy HMPL-A830. #Oncology #Biotech #Cancer #Health Disclaimer: This is NOT a financial advice

024 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 07/09/2026

Norroy Bioscience has received NMPA clearance to begin a pivotal Phase III trial of its PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. #Oncology #RadioligandTherapy #Biotech Disclaimer: This is NOT a financial advice

011 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 07/09/2026

Akeso says ivonescimab met the overall survival key secondary endpoint versus pembrolizumab in the HARMONi-2 trial, though specific data remains undisclosed pending a future conference. #Biotech #Biotechnology #Health #HealthInnovation Disclaimer: This is NOT a financial advice

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 07/09/2026

NurExone targets a potential H1 2027 IND for its preclinical ExoPTEN spinal-cord-injury program. #Biotech #Biotechnology #Health #HealthInnovation Disclaimer: This is NOT a financial advice

011 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 03/09/2026

Rakovina closes a C$1.99M financing for three preclinical, AI-designed cancer programs. #Biotech #AI #Oncology #Cancer #Biotechnology #Health Disclaimer: This is NOT a financial advice.

000 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 02/09/2026

Ascletis has dosed the first participant in its Phase III program for ASC30, an oral GLP-1 pill for chronic weight management, with topline data expected in 2028. #Obesity #GLP1 #Biotech Disclaimer: This is NOT a financial advice

011 0

Biotech Stock Daily @biotechstockdaily.bsky.social · 02/09/2026

Astellas Pharma has entered a voluntary drug pricing agreement with the U.S. government, joining eight other companies in the latest round of the Most Favored Nation pricing program. #USA #Biotech #Biotechnology #Health #PricingProgram Disclaimer: This is NOT a financial advice

111 0